Dr. Reddy’s Laboratories Ltd. ADR [RDY] stock is trading at $14.48, down -1.43%. An important factor to consider is whether the stock is rising or falling in short-term value. The RDY shares have gain 1.12% over the last week, with a monthly amount glided 2.19%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dr. Reddy’s Laboratories Ltd. ADR [NYSE: RDY] stock has seen the most recent analyst activity on January 11, 2024, when Jefferies downgraded its rating to a Underperform. Previously, HSBC Securities downgraded its rating to Hold on August 29, 2023. On May 18, 2023, downgrade downgraded it’s rating to Mkt Perform. BofA Securities upgraded its rating to a Buy. JP Morgan initiated its recommendation with a Underweight. Credit Suisse downgraded its rating to Underperform for this stock on November 14, 2022.
Dr. Reddy’s Laboratories Ltd. ADR [RDY] stock has fluctuated between $13.26 and $16.89 over the past year. Dr. Reddy’s Laboratories Ltd. ADR [NYSE: RDY] shares were valued at $14.48 at the most recent close of the market.
Analyzing the RDY fundamentals
Dr. Reddy’s Laboratories Ltd. ADR [NYSE:RDY] reported sales of 3.60B for the trailing twelve months, which represents a growth of 14.98%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.19 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.42 points at the first support level, and at 14.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.57, and for the 2nd resistance point, it is at 14.66.
Ratios To Look Out For
For context, Dr. Reddy’s Laboratories Ltd. ADR’s Current Ratio is 1.92. On the other hand, the Quick Ratio is 1.36, and the Cash Ratio is 0.09. Considering the valuation of this stock, the price to sales ratio is 3.35, the price to book ratio is 3.32 and price to earnings (TTM) ratio is 18.88.
Transactions by insiders
Recent insider trading involved Israeli Erez, Officer, that happened on Jul 29 ’24 when 65500.0 shares were purchased.
